Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial) by Jonathan Brett, Celia Morgan, Nadine Ezard, Brendan Clifford, Krista J Siefried, Robert May, Liam Acheson, Kathryn Fletcher, Harriet MacDonald, Gillinder Bedi, Alexandre Guerin, Elizabeth Knock, Michael Millard, Jess Doumany

“…In addition to direct antidepressant properties, ketamine is hypothesised to increase synaptogenesis and facilitate neuroplasticity, in turn prolonging and enhancing the effects of psychotherapy. …”
Get full text

Therapeutic potential of rutin in premenstrual depression: evidence from in vivo and in vitro studies by Xiangjun Wang, Xiaowen Xia, Xianliang Song, Yi Zhou, Mingyu Ma, Yashuang Ren, Xitai Chen, Zenghui Xia, Yinghui Guo, Chunhong Song

“…Rutin is a natural flavonol glycoside with various pharmacological properties including antidepressant. The study of the efficacy and mechanism of action of rutin in PMDD-depressed subtype model rats plays an important role in the discovery of new drugs for the treatment of PMDD.MethodsBinding of rutin to gamma-aminobutyric acid type A receptors (GABAA receptors) was probed using molecular docking, microscale thermophoresis, radioactive receptor ligand binding assay and cell membrane clamp experiment. …”
Get full text

Relationship between pharmacotherapy for major depressive disorder and healthcare utilisation in British Columbia, Canada: a retrospective population-based cohort by Sonya Cressman, Louisa Edwards, Kimberlyn McGrail, Stirling Bryan, Alison Hoens, Rohit Vijh, Sandra Peterson, Zeina Waheed, Mary Bunka, Nick Pang, Shahzad Ghanbarian, Gavin Wong, Linda Riches, Jehannine Austin

“…Objectives To describe the population that meets the criteria for major depressive disorder (MDD) in British Columbia (BC), compare patterns of healthcare utilisation between those with MDD who are and are not prescribed pharmacotherapy, and assess these relationships in models that control for potential confounding variables.Design We used a population cross-sectional study design among a cohort of individuals living with MDD and examined the relationship between pharmacotherapy and healthcare utilisation between 2019 and 2020 using linked billing and administrative data.Setting This study identified individuals with MDD using a validated case definition of International Classification of Diseases (ICD) codes in BC, Canada.Participants The final study cohort included 549 029 adult participants who met the MDD case definition.Explanatory variable Explanatory variable was the use of prescription antidepressant medication during the study period, based on BC PharmaNet data.Covariates Covariates include sociodemographic characteristics (age, sex, urban/rural residence, neighbourhood income quintile and comorbidities).Primary outcome measure Primary outcome measure was healthcare utilisation (outpatient physician visits, emergency department (ED) visits and hospitalisations).Results We stratified our analysis based on whether study participants were classified as ‘recently incident’ or ‘actively prevalent’. …”
Get full text